Skip to content

Comparison of two combination of antibiotics for Extensively drug resistant Gram Negative Bacteria in ICU patients

Comparison of ceftazidime-avibactam plus aztreonam with meropenem plus colistin in Intensive Care Unit patients with Extensively drug resistant (XDR) Gram-Negative Bacterial (GNB) infection- a Prospective Observational study

Status
Active, not recruiting
Phases
Phase 4
Study type
Observational
Source
CTRI
Registry ID
CTRI/2020/03/024343
Enrollment
80
Registered
2020-03-30
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: B962- Escherichia coli [E. coli ] as thecause of diseases classified elsewhere Health Condition 2: B961- Klebsiella pneumoniae [K. pneumoniae] as the cause of diseases classified elsewhere Health Condition 3: B965- Pseudomonas (aeruginosa) (mallei)(pseudomallei) as the cause of diseases classified elsewhere

Interventions

Control Intervention1: NIL: NIL

Sponsors

FMRI
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Any body-fluid culture positive for gram negative Enterobacteriaceae 2. Sensitive to only one or two group of antibiotics (carbapenem resistant) 3. Onset of symptoms >=48 hours after admission to hospital or history of hospital admission in past 30 days 4.>=1 systemic sign of infection -Fever (temperature >38°C) or hypothermia (temperature -White blood cell count >11,000 or 15% band forms

Exclusion criteria

Exclusion criteria: 1.On triple/multi drug therapy for GNB 2.Patient refusal to participate in the study 3.Follow up drop outs 4.Need to change to other drugs during the study 5.Known allergy to study drugs 6.Previous inclusion in the study 7.Polymicrobial infection where one or more of the clinically-significant gram-negative bacteria are susceptible to any beta-lactam 8.Pregnant patients.

Design outcomes

Primary

MeasureTime frame
clinical success with respect to following: 1.Fever 2.TLC 3. Patient alive 4.Systolic blood pressure 90 mmHg without need for vasopressor support 5.Stable or improved SOFA score 6. For patients with HAP/ VAP, PaO2/FiO2 ratio stable or improved 7. For patients with bacteraemia, no growth of the initial isolate in blood cultures taken on day 14 if patient still febrileTimepoint: Day 1- ie on day of culture positivity Day 14

Secondary

MeasureTime frame
Evaluate the 28-day mortalityTimepoint: Day 28 of Culture positivity

Countries

India

Contacts

Public ContactDivya Gupta

Fortis Memorial Research Institute, Gurgaon

sandeep.dewan@fortishealthcare.com9971112198

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026